Novartis AG (NVS)
After hours:
| Previous Close | 93.08 |
| Open | 92.85 |
| Bid | 92.00 x 900 |
| Ask | 94.15 x 800 |
| Day's Range | 92.35 - 92.93 |
| 52 Week Range | 92.19 - 108.78 |
| Volume | |
| Avg. Volume | 1,498,658 |
| Market Cap | 189.216B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 22.58 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.78 (4.06%) |
| Ex-Dividend Date | Mar 07, 2024 |
| 1y Target Est | N/A |
- Reuters
US FDA mandates label updates on CAR-T cancer therapies
The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.
- Zacks
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- Zacks
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
